Serum values of tumour necrosis factor-α and of soluble tumour necrosis factor-R55 in melanoma patients

Melanoma Research

Volumn 10, Issue 3, 2000, Pages 253-258

  Ocvirk, J ^a   Stabuc, B ^a   Rudolf, Z ^a   Galvani, V ^a   Curin Serbec, V ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Metastatic melanoma; Soluble TNF receptors; TNF

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; LOMUSTINE; MONOCLONAL ANTIBODY; SOLUBLE TUMOR NECROSIS FACTOR R55; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0033778136     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200006000-00007     Document Type: Article

References (24)

1. The biology of cachexin/TNF: A primary mediator of the host response
2. Pattern of soluble TNF receptors I and II in sepsis
3. Cytokine and HIV infection: Is AIDS a tumor necrosis factor disease?
4. The tumor necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis
5. Two TNF receptors
6. Two human TNF receptors have similar extracellular, but distinct intracellular domain sequences
7. Two tumor necrosis factor receptors: Structure and function
8. Mechanism of action of the tumor necrosis factor and lymphotoxin ligand-receptor system
9. Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis
10. Isolation and characterisation of tumor necrosis factor binding protein from human urine
11. Slow release of soluble TNF receptors by monocytes in vitro
12. Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans
13. Multifaceted inhibition of anti-tumor immune mechanisms by soluble tumor necrosis factor receptor type I
14. Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients
15. Tumor necrosis factor (TNF) soluble receptors in malignant melanoma: Correlation with soluble ICAM-1 levels
16. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients
17. Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy
18. Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer
19. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer
20. Plasma levels of tumor necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients
21. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients
22. Leukemic cells in hairy cell leukemia and B cell chronic lymphocytic leukemia release soluble TNF receptors
23. Serum levels of tumor necrosis factor-α in patients with B-cell chronic lymphocytic leukemia
24. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia